RxDoctor Payments Data

Konstantin Astafurov

Retina Specialist · Little Silver, NJNPI 1730574872

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 46 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 50.2% of the total. That places this record below the midpoint for retina specialist clinicians in NJ, where the typical reported total is $2,776.

$1,382in general payments, 2019–2025

Across 46 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$694
  • Apellis Pharmaceuticals, Inc.$189
  • Astellas Pharma US Inc$119
  • Biogen$100
  • Genentech USA, Inc.$57
  • Alimera Sciences, Inc.$57
  • plus $166 from 5 others
$13,493in research payments, 2019–2025

Across 181 payments — averaging $74.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$8K
  • Notal Vision, Inc.$6K

What the payments were for

  • Food & beverage$1,382100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,382 in reported general payments places this provider in the 30th percentile of 35 retina specialist providers in New Jersey.

See all retina specialist providers in New Jersey

Medicare billing

Part B allowed, 2024
$2,159,957
Medicare patients
693
Services billed
16,667

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bromfenac Sodium52$6,777
Prednisolone Acetate109$6,746
ProlensaBromfenac Sodium12$4,192
Difluprednate31$2,460
Ketorolac Tromethamine72$2,354
Atropine Sulfate51$1,798
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat84$1,260
Latanoprost56$796
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha56$579
ErythromycinErythromycin Base12$128
Prednisone12$58
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$41

Paid to pharmacies, not to this prescriber.

Other retina specialist in Little Silver

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →